161 related articles for article (PubMed ID: 35142560)
1. Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients.
Gualano B; Saad CGS; Sieczkowska SM; Lemes ÍR; da Silva RP; Pinto AJ; Mazzolani BC; Smaira FI; Gil S; Oliveira-Junior G; Aikawa NE; Medeiros-Ribeiro AC; Silva CA; Yuki EFN; Pasoto SG; Pereira RMR; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Roschel H; Bonfa E
J Appl Physiol (1985); 2022 Mar; 132(3):682-688. PubMed ID: 35142560
[TBL] [Abstract][Full Text] [Related]
2. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
[TBL] [Abstract][Full Text] [Related]
3. Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases.
Gualano B; Lemes IR; Silva RP; Pinto AJ; Mazzolani BC; Smaira FI; Sieczkowska SM; Aikawa NE; Pasoto SG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Silva CA; Swinton P; Hallal PC; Roschel H; Bonfa E
Brain Behav Immun; 2022 Mar; 101():49-56. PubMed ID: 34954325
[TBL] [Abstract][Full Text] [Related]
4. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
5. Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
Pasoto SG; Halpern ASR; Guedes LKN; Ribeiro ACM; Yuki ENF; Saad CGS; da Silva CAA; de Vinci Kanda Kupa L; Villamarín LEB; de Oliveira Martins VA; Martins CCMF; Deveza GBH; Leon EP; Bueno C; Pedrosa TN; Santos REB; Soares R; Aikawa NE; Bonfa E
Clin Rheumatol; 2022 Jul; 41(7):2079-2089. PubMed ID: 35306594
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.
Pereira RMR; Dagostin MA; Caparbo VF; Sales LP; Pasoto SG; Silva CA; Yuki EFN; Saad CGS; Medeiros-Ribeiro AC; Kupa LVK; Fusco SRG; Martins VAO; Martins CCMF; Barbas CV; Shinjo SK; Aikawa NE; Bonfa E
Clinics (Sao Paulo); 2023; 78():100150. PubMed ID: 36529052
[TBL] [Abstract][Full Text] [Related]
7. Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients.
Gualano B; Lemes ÍR; da Silva RP; Pinto AJ; Mazzolani BC; Smaira FI; Sieczkowska SM; Aikawa NE; Pasoto S; Medeiros-Ribeiro AC; Saad C; Yuk E; Silva C; Swinton P; Hallal PC; Roschel H; Bonfa E
Scand J Med Sci Sports; 2022 Oct; 32(10):1510-1515. PubMed ID: 35844042
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
Front Immunol; 2022; 13():967051. PubMed ID: 36159863
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
Li JX; Wu SP; Guo XL; Tang R; Huang BY; Chen XQ; Chen Y; Hou LH; Liu JX; Zhong J; Pan HX; Shi FJ; Xu XY; Li ZP; Zhang XY; Cui LB; Tan WJ; Chen W; Zhu FC;
Lancet Respir Med; 2022 Aug; 10(8):739-748. PubMed ID: 35605625
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
[TBL] [Abstract][Full Text] [Related]
11. Physical Activity: A Strategy to Improve Antibody Response to a SARS-CoV-2 Vaccine Booster Dose in Patients With Autoimmune Rheumatic Diseases.
Gualano B; Sieczkowska SM; Lemes ÍR; da Silva RP; Pinto AJ; Mazzolani BC; Smaira FI; Aikawa NE; Kupa LVK; Pasoto SG; Medeiros-Ribeiro AC; Saad CGS; Yuk EFN; Silva CA; Swinton P; Hallal PC; Roschel H; Bonfa E
J Phys Act Health; 2023 Apr; 20(4):311-316. PubMed ID: 36870351
[TBL] [Abstract][Full Text] [Related]
12. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
Araujo CSR; Medeiros-Ribeiro AC; Saad CGS; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Silva MSR; Yuki EFN; Pasoto SG; Pedrosa T; Kupa LVK; Zou G; Pereira RMR; Silva CA; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 Jun; 81(6):889-897. PubMed ID: 35193873
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Signorelli F; Balbi GGM; Aikawa NE; Silva CA; Kupa LVK; Medeiros-Ribeiro AC; Yuki EF; Pasoto SG; Saad CG; Borba EF; Seguro LPC; Pedrosa T; Oliveira VAA; Costa ALCS; Ribeiro CT; Santos REB; Andrade DCO; Bonfá E
Lupus; 2022 Jul; 31(8):974-984. PubMed ID: 35593174
[TBL] [Abstract][Full Text] [Related]
14. [Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].
Pan HX; Huang BY; Deng Y; Chu K; Hu JL; Zhu DD; Wu JL; Zhang L; Wang M; Huang WJ; Tan WJ
Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(4):279-285. PubMed ID: 35073677
[No Abstract] [Full Text] [Related]
15. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
Aikawa NE; Kupa LVK; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Rojo PT; Pereira RMR; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Halpern ASR; Fuller R; Souza FHC; Guedes LKN; Assad APL; Moraes JCB; Lopes MRU; Martins VAO; Betancourt L; Ribeiro CT; Sales LP; Bertoglio IM; Bonoldi VLN; Mello RLP; Balbi GGM; Sartori AMC; Antonangelo L; Silva CA; Bonfa E
Ann Rheum Dis; 2022 Jul; 81(7):1036-1043. PubMed ID: 35277389
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC; Ibrahim KY; Picone CM; Alves APPS; Aniceto EV; Santiago MR; Parmejani PSS; Aikawa NE; Medeiros-Ribeiro AC; Pasoto SG; Yuki EFN; Saad CGS; Pedrosa T; Lara AN; Ceneviva C; Bonfa E; Kallas EG; Avelino-Silva VI
Lancet HIV; 2022 May; 9(5):e323-e331. PubMed ID: 35338835
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines.
Luo W; Gan J; Luo Z; Li S; Wang Z; Wu J; Zhang H; Xian J; Cheng R; Tang X; Liu Y; Yang L; Mou Q; Zhang X; Chen Y; Wang W; Wang Y; Bai L; Wei X; Zhang R; Yang L; Chen Y; Yang L; Li Y; Liu D; Li W; Chen L
Signal Transduct Target Ther; 2024 Feb; 9(1):41. PubMed ID: 38355676
[TBL] [Abstract][Full Text] [Related]
18. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
Aikawa NE; Kupa LVK; Silva CA; Saad CGS; Pasoto SG; Yuki EFN; Fusco SRG; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Pereira RMR; Chasin ACS; Shimabuco AY; Luppino-Assad AP; Leon EP; Lopes MH; Antonangelo L; Medeiros-Ribeiro AC; Bonfa E
Rheumatology (Oxford); 2022 Dec; 62(1):480-485. PubMed ID: 35639644
[TBL] [Abstract][Full Text] [Related]
19. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Yuki EFN; Borba EF; Pasoto SG; Seguro LP; Lopes M; Saad CGS; Medeiros-Ribeiro AC; Silva CA; de Andrade DCO; Kupa LVK; Betancourt L; Bertoglio I; Valim J; Hoff C; Formiga FFC; Pedrosa T; Kallas EG; Aikawa NE; Bonfa E
Arthritis Care Res (Hoboken); 2022 Apr; 74(4):562-571. PubMed ID: 34806342
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients.
Silva CA; Medeiros-Ribeiro AC; Kupa LVK; Yuki EFN; Pasoto SG; Saad CGS; Fusco SRG; Pereira RMR; Shinjo SK; Halpern ASR; Borba EF; Souza FHC; Guedes LKN; Miossi R; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Andrade DCO; Seguro LPC; Fuller R; Sampaio-Barros PD; Assad APL; Moraes JCB; Goldenstein-Schainberg C; Giardini HAM; Silva HC; Martins VAO; Villamarin LEB; Novellino RS; Sales LP; Araújo CSR; Silva MSR; Filho DMN; Lopes MH; Duarte AJS; Kallas EG; Aikawa NE; Bonfa E
Nat Commun; 2022 Oct; 13(1):5801. PubMed ID: 36192386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
